Q-omics provides the consensus-scored LRRC3C profile across patient tissues and cancer cell-line models. LRRC3C expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, LRRC3C is differentially expressed in 6, with the highest sampling consensus in KICH. Additionally, LRRC3C RNA expression shows 10,996 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight BLCA, KICH, and TGCT as cancer lineages where LRRC3C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LRRC3C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LRRC3C survival associations across molecular data types. LRRC3C RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LRRC3C RNA expression–survival associations across cancer types. High LRRC3C expression shows unfavorable associations in KIRP and COAD, but favorable associations in BLCA, UVM, LUSC and KIRC. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify BLCA as the clearest survival context for LRRC3C RNA expression.
This table summarizes LRRC3C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for LRRC3C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LRRC3C shows lower tumor expression in KICH, LUSC, THCA, KIRC, BLCA and LUAD. The KICH box plot shows higher LRRC3C RNA expression in normal versus tumor tissue (log2 FC = −0.202, t-test p < 0.001).
This table shows molecular features associated with LRRC3C in patient tissues and cancer cell lines. In patient samples, LRRC3C shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, LRRC3C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Lymphoma.
